You are currently logged into
Cancer Health Directory - My Account or Log Out
Cancer Health Cancer Health
  • Home
  • News
    • News
    • Newsfeed
    • Treatment News
    • Features
    • Opinions
    • Conferences
    • Slideshows
    • Cancer Health TV
    • By Author
    • RSS Links
  • Cancer Basics
    • Cancer 101
    • Newly Diagnosed
    • Living with Cancer
    • Cancer Treatment
    • Cancer Medications
    • Breast Cancer
    • Colon Cancer
    • Liver Cancer
    • Lung Cancer
    • Prostate Cancer
    • More Types of Cancer
    • Resources
  • Hot Topics
    • Coronavirus (COVID-19)
    • Health Equity
    • Cancer Treatment
    • Car-T Therapy
    • Caregivers
    • Chemotherapy
    • Immunotherapy
    • Marijuana
    • Mental Health
    • Quality of Life
  • Magazine
    • Magazine
    • Current Issue
    • Archives
    • Digital Editions
    • Cancer Health Focus
    • Bulk Subscriptions
    • Email Newsletters
  • Blogs
    • Blogs
    • Recent Posts
    • Browse Bloggers
    • RSS Links
  • Community
    • Cancer Health Stories
    • Cancer Health Forums
    • Ask Cancer Health
    • Polls
    • Surveys
    • Quizzes
    • Calendar
    • Volunteer Jobs
    • Bookstore
    • Amazon Store
  • About Us
    • About Us
    • Masthead
    • Advertise
    • Awards
    • Contact Us
  • Facebook
  • Twitter

© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

© 2021 Smart + Strong.
All Rights Reserved.
Terms of use and
Your privacy.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.

Advertisement

Share


Twitter
Facebook
Pinterest
Tumblr
Email

#Tagrisso

Tweet
  • Share

FDA Approves First Adjuvant Therapy for Most Common Type of Lung Cancer

Tagrisso (osimertinib) was approved for non-small cell lung cancer patients with EGFR-positive tumors.

Tagrisso

Scan Results and the One Question Nobody Asks

If your life depends on it, wouldn’t you want to know EVERYTHING that might help?

Osimertinib binds to specific mutated forms of EGFR proteins, including one called T790M that is linked to resistance to other EGFR-targeted drugs.

Osimertinib Improves Survival in Advanced Lung Cancer with EGFR Mutations

The survival improvement did not come at the cost of safety; the investigators saw no increase in serious side effects.

What Is Targeted Therapy?

Precision medicine matches patients with the treatments most likely to work for them.

FDA Approves Tagrisso for First-Line Lung Cancer Treatment

Osimertinib led to improved progression-free survival in people with common EGFR mutations.

Advertisement

Stay Logged In?

You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.

You Have Been Logged Out

Click here to log back in.